SP-EPs affect 18%-53% of patients with neurofibromatosis type 2, with clinical symptoms appearing in less than 20% of cases [15]; 39% of SP-EP patients had NF2 insertion/deletion or nonsense mutations [12]. This evidence concerns the gene NF2 and neurofibromatosis.